uniQure (NASDAQ:QURE) Shares Up 7.2% - Should You Buy?

uniQure (NASDAQ:QURE - Get Free Report) shares shot up 7.2% on Thursday . The company traded as high as $16.16 and last traded at $16.03. 468,023 shares traded hands during trading, a decline of 75% from the average session volume of 1,899,432 shares. The stock had previously closed at $14.96.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on QURE. Cantor Fitzgerald upgraded shares of uniQure to a "strong-buy" rating in a report on Monday, May 19th. Chardan Capital restated a "buy" rating and set a $38.00 target price on shares of uniQure in a report on Friday, May 30th. Guggenheim reiterated a "buy" rating and issued a $28.00 price objective on shares of uniQure in a report on Monday, May 12th. Wells Fargo & Company decreased their price objective on shares of uniQure from $35.00 to $30.00 and set an "equal weight" rating on the stock in a report on Friday, February 28th. Finally, HC Wainwright reiterated a "buy" rating and issued a $70.00 price objective on shares of uniQure in a report on Thursday, May 29th. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $37.82.

uniQure Price Performance

The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The company's 50 day moving average is $12.76 and its 200 day moving average is $13.11. The firm has a market capitalization of $945.98 million, a price-to-earnings ratio of -3.48 and a beta of 0.08.

uniQure (NASDAQ:QURE - Get Free Report) last released its quarterly earnings results on Friday, May 9th. The biotechnology company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.25. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The business had revenue of $1.57 million for the quarter, compared to the consensus estimate of $5.93 million. On average, equities research analysts anticipate that uniQure will post -3.75 earnings per share for the current fiscal year.

Hedge Funds Weigh In On uniQure

Several institutional investors and hedge funds have recently modified their holdings of the business. Woodline Partners LP grew its stake in shares of uniQure by 25.0% in the first quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company's stock valued at $1,864,000 after acquiring an additional 35,175 shares in the last quarter. 683 Capital Management LLC lifted its position in uniQure by 1.6% during the first quarter. 683 Capital Management LLC now owns 1,550,000 shares of the biotechnology company's stock worth $16,430,000 after purchasing an additional 25,000 shares during the period. Vestal Point Capital LP lifted its position in uniQure by 58.4% during the first quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company's stock worth $50,801,000 after purchasing an additional 1,767,572 shares during the period. Birchview Capital LP lifted its position in uniQure by 343.5% during the first quarter. Birchview Capital LP now owns 88,697 shares of the biotechnology company's stock worth $940,000 after purchasing an additional 68,697 shares during the period. Finally, Nantahala Capital Management LLC lifted its position in uniQure by 3.8% during the first quarter. Nantahala Capital Management LLC now owns 2,755,962 shares of the biotechnology company's stock worth $29,213,000 after purchasing an additional 101,598 shares during the period. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.